Dehydrocorydaline attenuates bleomycin-induced pulmonary fibrosis by inhibiting fibroblast activation
Our study implied that DHC hold a promise therapeutic approach against PF by suppressing fibroblast activation. The safety and efficacy of DHC have been preliminary demonstrated in a mouse model.
Authors
- Huilan Zhang (ORCID: https://orcid.org/0000-0002-2366-7321)
- Huihui Yue (ORCID: https://orcid.org/0000-0002-6719-2268)
- Ruihan Dong
- Fengqin Zhang (ORCID: https://orcid.org/0000-0001-9479-2456)
- Huiguo Liu (ORCID: https://orcid.org/0000-0002-9722-833X)
- Jianhan He
- Shufei Zhang (ORCID: https://orcid.org/0000-0002-4614-4718)
- Ke Wang (ORCID: https://orcid.org/0000-0002-2824-1047)
- Xuewen Wang (ORCID: https://orcid.org/0000-0001-8246-0999)
- Zhaoxing Dong (ORCID: https://orcid.org/0000-0003-1336-149X)
- Dan‐Lei Yang (ORCID: https://orcid.org/0009-0009-8003-8140)
Institutions
- Tongji Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Respiratory Research
- Published
- 2025-04-12
- DOI
- https://doi.org/10.1186/s12931-025-03218-5
- Citations
- 3
- Primary Topic
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
- Tongji University